Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | PNP | P00491 | 5/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | POLG | P54098 | 2/20 | 0.43 |
| ▸ | POLA1 | P09884 | 1/20 | 0.42 |
| ▸ | HPRT1 | P00492 | 8/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triphosphate SCHEMBL28101758 | 0.94 | PNP (0.50) | KDM4EALDH1A1LMNAGLAPMP22 | |
| Guanine SCHEMBL663745 | 0.91 | KDM4E (0.53) | KDM4EALDH1A1LMNAGLAPMP22 | |
| Guanine SCHEMBL76053 | 0.91 | KDM4E (0.53) | KDM4EALDH1A1LMNAGLAPMP22 | |
| Guanine SCHEMBL5372452 | 0.90 | KDM4E (0.51) | KDM4EALDH1A1LMNAGLAPMP22 | |
| Guanine SCHEMBL15948930 | 0.88 | KDM4E (0.50) | KDM4EALDH1A1LMNAGLAPMP22 | |
| Guanine SCHEMBL4658042 | 0.86 | ALDH1A1 (0.61) | KDM4EALDH1A1LMNAGLAPMP22 | |
| Guanine SCHEMBL5259 | 0.86 | ALDH1A1 (0.61) | KDM4EALDH1A1LMNAGLAPMP22 | |
| Guanine SCHEMBL27542045 | 0.85 | HSD17B10 (0.56) | KDM4EALDH1A1LMNAGLAPMP22 | |
| Guanine SCHEMBL2895087 | 0.85 | ALDH1A1 (0.59) | KDM4EALDH1A1LMNAGLAPMP22 | |
| Guanine SCHEMBL21611717 | 0.85 | ALDH1A1 (0.59) | KDM4EALDH1A1LMNAGLAPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 330 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4087611-A1 | SHP2 INHIBITOR DOSING AND METHODS OF TREATING CANCER | Revolution Medicines, Inc. (US) | 2022-11-16 | — | — | EP | claimed |
| CN-114929279-A | Methods of administering SHP2 inhibitors and treating cancer | 锐新医药公司 | 2022-08-19 | — | — | CN | claimed |
| US-20220110871-A1 | PHARMACEUTICAL PREPARATION OF CARBOHYDRATES FOR THERAPEUTIC USE | GLYCOMINE, INC. (US) | 2022-04-14 | — | — | US | claimed |
| EP-3954360-A2 | PHARMACEUTICAL PREPARATION OF CARBOHYDRATES FOR THERAPEUTIC USE | Glycomine, Inc. (US) | 2022-02-16 | — | — | EP | claimed |
| US-20200246266-A1 | PHARMACEUTICAL PREPARATION OF CARBOHYDRATES FOR THERAPEUTIC USE | GLYCOMINE, INC. (US) | 2020-08-06 | — | — | US | claimed |
| WO-2019034597-A1 | FORCE-RESPONSIVE POLYMERSOMES AND NANOREACTORS; PROCESSES UTILIZING THE SAME | ADOLPHE MERKLE INSTITUTE, UNIVERSITY OF FRIBOURG (CH) | 2019-02-21 | — | — | WO | claimed |
| US-20180036239-A1 | PHARMACEUTICAL PREPARATION OF CARBOHYDRATES FOR THERAPEUTIC USE | GLYCOMINE, INC. (US) | 2018-02-08 | — | — | US | claimed |
| US-20160228364-A1 | PHARMACEUTICAL PREPARATION OF CARBOHYDRATES FOR THERAPEUTIC USE | GLYCOMINE, INC. (US) | 2016-08-11 | — | — | US | claimed |
| EP-3046537-A2 | PHARMACEUTICAL PREPARATION OF CARBOHYDRATES FOR THERAPEUTIC USE | Glycomine, Inc. (US) | 2016-07-27 | — | — | EP | claimed |
| WO-2015053910-A2 | PHARMACEUTICAL PREPARATION OF CARBOHYDRATES FOR THERAPEUTIC USE | GLYCOMINE LLC (US) | 2015-04-16 | — | — | WO | claimed |
| US-20140329699-A1 | SYSTEMS AND METHODS FOR HIGH EFFICIENCY ELECTRONIC SEQUENCING AND DETECTION | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2014-11-06 | — | — | US | claimed |
| EP-2785868-A1 | SYSTEMS AND METHODS FOR HIGH EFFICIENCY ELECTRONIC SEQUENCING AND DETECTION | Genapsys Inc. (US) | 2014-10-08 | — | — | EP | claimed |
| WO-2013082619-A1 | SYSTEMS AND METHODS FOR HIGH EFFICIENCY ELECTRONIC SEQUENCING AND DETECTION | GENAPSYS, INC. (US) | 2013-06-06 | — | — | WO | claimed |
| US-8383597-B2 | G proteins in tumor growth and angiogenesis | CORNELL RESEARCH FOUNDATION, INC. (US) | 2013-02-26 | — | — | US | claimed |
| US-8173620-B2 | BHQ-caged nucleotide probes photolysable by two-photon excitation | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2012-05-08 | — | — | US | claimed |
| US-20100048502-A1 | BHQ-CAGED NUCLEOTIDE PROBES PHOTOLYSABLE BY TWO-PHOTON EXCITATION | NATIONAL SCIENCE FOUNDATION | 2010-02-25 | — | — | US | claimed |
| CN-101495504-A | Materials and methods for the generation of fully 2'-modified nucleic acid transcripts | ARCHEMIX CORP (US) | 2009-07-29 | — | — | CN | claimed |
| US-20080020994-A1 | G proteins in tumor growth and angiogenesis | CORNELL RESEARCH FOUNDATION, INC. (US) | 2008-01-24 | — | — | US | claimed |
| US-20260094669-A1 | EPITOPE PREDICTION VIA A LEARNED GENOTYPE NETWORK ACROSS CLASS II MHC ALLELES | SEATTLE PROJECT CORP (US) | 2026-04-02 | — | — | US | disclosed |
| WO-1994029727-A1 | INHIBITING PROTEIN INTERACTIONS | THE GENERAL HOSPITAL CORPORATION (US) | 1994-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260094669-A1 | EPITOPE PREDICTION VIA A LEARNED GENOTYPE NETWORK ACROSS CLASS II MHC ALLELES | MICA, HLA-DRB1, TAP2 | KDM4E 2641/4885ALDH1A1 4709/4885LMNA 948/4885 |
| US-20100048502-A1 | BHQ-CAGED NUCLEOTIDE PROBES PHOTOLYSABLE BY TWO-PHOTON EXCITATION | NUDT1, RECQL, PNP | KDM4E 971/4885ALDH1A1 1338/4885LMNA 1447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.